Another Merk-i-fied doctor is off to new horizons -- this time to a development company targeting future weight management drug candidates, per PR Newswires online:
. . . .Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has appointed John M. Amatruda, M.D. as chair of the company’s Science and Medical Advisory Board.
Amatruda was formerly vice president of clinical development for metabolism, atherosclerosis, and cardiovascular at Merck & Co., Inc., and served most recently as senior vice president and franchise head of Merck’s discovery research and drug development effort in diabetes and obesity.
"We are extremely pleased to have attracted a pharmaceutical research and development executive of Dr. Amatruda’s stature to chair our Science and Medical Advisory Board," said Stephen Benoit, MSDC’s chief executive officer. . . .
[Do stay tuned, but blogging will be spotty for a bit here.]
No comments:
Post a Comment